• Johnson & Johnson disclosed new three-year Phase 3 data for Tremfya in moderate to severe Crohn’s disease.
• Results were set for presentation at the American College of Gastroenterology 2026 annual meeting.
• Patients maintained symptom control and intestinal healing through three years across both maintenance dosing regimens.
• Safety through three years matched Tremfya’s established profile in Crohn’s disease, supporting long-term use in a chronic indication.
• Data strengthen the commercial case for Tremfya as a long-duration inflammatory bowel disease therapy, alongside its ulcerative colitis franchise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on October 13, 2026, and is solely responsible for the information contained therein.